We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: JPMorgan, Procter & Gamble, UnitedHealth, McDonald's and Philip Morris
Read MoreHide Full Article
For Immediate Release
Chicago, IL –November 27, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: JPMorgan (JPM - Free Report) , Procter & Gamble (PG - Free Report) , UnitedHealth (UNH - Free Report) , McDonald's (MCD - Free Report) and Philip Morris International (PM - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Stock Reports for JPMorgan, Procter & Gamble and UnitedHealth
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan, Procter & Gamble and UnitedHealth. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
JPMorgan's shares have outperformed the Zacks Major Regional Banks industry over the past six months (-3.7% vs. -7.7%). Also, the company has an impressive earnings surprise history, having surpassed the Zacks Consensus Estimate in each of the trailing four quarters.
Expansion into new markets, focus on strengthening the card business, rising rate environment and increasing loan demand will benefit the bank’s financials. Lower tax rates, strong balance sheet position and easing of stringent regulations are expected to offer some support.
However, dismal mortgage banking performance (as originations continue to decline) remains a major concern. This is expected to hurt the bank's non-interest income growth to some extent.
Procter & Gamble outperformed the Zacks Soap and Cleaning Materials industry in the past three months, gaining +9.7% vs +2.4%. This can be attributed to the company’s robust earnings history, having outpaced estimates for 14 straight quarters when it reported first-quarter fiscal 2019.
Moreover, earnings grew year over year. Also, sales beat estimates, though it remained flat due to adverse currency fluctuations – which acted as a major deterrent in the first quarter and is likely to remain a concern in the second quarter. Also, the company has been witnessing strained margins for last few quarters due to higher commodity and shipping costs, adverse currency, increased business investments and aggressive pricing from private-label products. Soft baby care business is also a concern.
Nevertheless, the company is focused on improving productivity and cost savings to boost margins. Its focus on product improvement, packaging and marketing initiatives is encouraging.
Shares of Buy-ranked UnitedHealth have outperformed the Zacks Medical Insurance industry's rally in the past year (up +23.1% vs. +22.4%). The company's performance is being backed by higher revenues and strength in both segments — UnitedHealthcare and Optum — plus membership growth.
The company's robust Government is also driving long-term growth. Its international business and strong capital position are the other positives. The company’s raised earnings guidance for 2018 should instill optimism among its investors.
However, the company is seeing membership decline in Commercial segment. Two significant acquisitions would intensify the competition for UnitedHealth Group.
Other noteworthy reports we are featuring today include McDonald's and Philip Morris International.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: JPMorgan, Procter & Gamble, UnitedHealth, McDonald's and Philip Morris
For Immediate Release
Chicago, IL –November 27, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: JPMorgan (JPM - Free Report) , Procter & Gamble (PG - Free Report) , UnitedHealth (UNH - Free Report) , McDonald's (MCD - Free Report) and Philip Morris International (PM - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Stock Reports for JPMorgan, Procter & Gamble and UnitedHealth
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan, Procter & Gamble and UnitedHealth. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
JPMorgan's shares have outperformed the Zacks Major Regional Banks industry over the past six months (-3.7% vs. -7.7%). Also, the company has an impressive earnings surprise history, having surpassed the Zacks Consensus Estimate in each of the trailing four quarters.
Expansion into new markets, focus on strengthening the card business, rising rate environment and increasing loan demand will benefit the bank’s financials. Lower tax rates, strong balance sheet position and easing of stringent regulations are expected to offer some support.
However, dismal mortgage banking performance (as originations continue to decline) remains a major concern. This is expected to hurt the bank's non-interest income growth to some extent.
Procter & Gamble outperformed the Zacks Soap and Cleaning Materials industry in the past three months, gaining +9.7% vs +2.4%. This can be attributed to the company’s robust earnings history, having outpaced estimates for 14 straight quarters when it reported first-quarter fiscal 2019.
Moreover, earnings grew year over year. Also, sales beat estimates, though it remained flat due to adverse currency fluctuations – which acted as a major deterrent in the first quarter and is likely to remain a concern in the second quarter. Also, the company has been witnessing strained margins for last few quarters due to higher commodity and shipping costs, adverse currency, increased business investments and aggressive pricing from private-label products. Soft baby care business is also a concern.
Nevertheless, the company is focused on improving productivity and cost savings to boost margins. Its focus on product improvement, packaging and marketing initiatives is encouraging.
Shares of Buy-ranked UnitedHealth have outperformed the Zacks Medical Insurance industry's rally in the past year (up +23.1% vs. +22.4%). The company's performance is being backed by higher revenues and strength in both segments — UnitedHealthcare and Optum — plus membership growth.
The company's robust Government is also driving long-term growth. Its international business and strong capital position are the other positives. The company’s raised earnings guidance for 2018 should instill optimism among its investors.
However, the company is seeing membership decline in Commercial segment. Two significant acquisitions would intensify the competition for UnitedHealth Group.
Other noteworthy reports we are featuring today include McDonald's and Philip Morris International.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.